

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**WEGO 威高**

山東威高集團醫用高分子製品股份有限公司

**Shandong Weigao Group Medical Polymer Company Limited \***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1066)**

**FURTHER DELAY IN DESPATCH OF  
CIRCULAR IN RELATION TO MAJOR  
AND DISCLOSEABLE TRANSACTIONS**

Reference is made to the announcement (the “**Proposed Transaction Announcement**”) of Shandong Weigao Group Medical Polymer Company Limited (the “**Company**”) dated 15 June 2016 in relation to, among others, the Proposed Transaction and the announcements (the “**Delay Announcements**”, together with the Proposed Transaction Announcement, the “**Announcements**”) of the Company dated 6 July 2016, 28 July 2016, 18 August 2016, 29 September 2016, 20 October 2016 and 3 November 2016, respectively, in relation to the delay in despatch of the Circular. Capitalised terms used herein shall have the same meanings as defined in the Announcements unless the context requires otherwise.

As disclosed in the Delay Announcement dated 3 November 2016, the Company expected to despatch the Circular containing, among other things, further details of the Proposed Transaction, a letter from the independent board committee of the Company and a letter from the independent financial adviser of the Company together with a notice convening the EGM on or before 30 November 2016.

As the valuation of the equity interest in Weigao Ortho and the Winbase Assets as at 31 December 2015 has to be updated pursuant to the PRC regulations, the parties to the Proposed Transaction are required to arrange for a further valuation of the equity interest in Weigao Ortho and the Winbase Assets. As a result, the despatch of the Circular will be further postponed. The Company will make an announcement in relation to the update of the valuation in due course.

By Order of the Board  
**Shandong Weigao Group Medical Polymer Company Limited**  
**Zhang Hua Wei**  
*Chairman*

Weihai, Shandong, the PRC, 29 November 2016

As at the date of this announcement, the Board comprises:

Mr. Zhang Hua Wei (*Executive Director*)

Mr. Wang Yi (*Executive Director*)

Mr. Gong Jian Bo (*Executive Director*)

Mr. Xia Lie Bo (*Executive Director*)

Mrs. Zhou Shu Hua (*Non-executive Director*)

Mr. Lo Wai Hung (*Independent non-executive Director*)

Mr. Li Jia Miao (*Independent non-executive Director*)

Mrs. Fu Ming Zhong (*Independent non-executive Director*)

Mrs. Wang Jin Xia (*Independent non-executive Director*)

\* *For illustration purpose only*